Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 169-179

  Migliori, Giovanni Battista ^a   Sotgiu, Giovanni ^b   Gandhi, Neel R ^c   Falzon, Dennis ^a   DeRiemer, Kathryn ^d   Centis, Rosella ^a   Hollm Delgado, Maria Graciela ^e   Palmero, Domingo ^f   Pérez Guzmán, Carlos ^g   Vargas, Mario H ^g   D'Ambrosio, Lia ^a   Spanevello, Antonio ^h   Bauer, Melissa ^e   Chan, Edward D ⁱ   Schaaf, H Simon ^j   Keshavjee, Salmaan ^k   Holtz, Timothy H ^l   Menzies, Dick ^e   Ahuja, S ^m   Ashkin, D ⁿ   Avendano, M ^m   Banerjee, R ^m   Bayona, J N ^m   Becerra, M C ^m   Benedetti, A ^m   Burgos, M ^m   Chiang, C Y ^m   Cox, H ^m   Dung, N H ^m   Enarson, D ^m   Flanagan, K ^o   Flood, J ^m   Garcia Garcia, L ^p   Granich, R M ^m   Iseman, M D ^m   Jarlsberg, L G ^m   Kim, H R ^m   Koh, W J ^m   Lancaster, J ^m   Lange, C ^m   De Lange, W C M ^m   Leimane, V ^q   Leung, C C ^m   Li, J ^m   Mishustin, S P ^m   Mitnick, C D ^m   Narita, M ^m   O'Riordan, P ^r   Pai, M ^m   Park, S K ^m   Pasvol, G ^r   Pena, J ^m   Ponce De Leon, A ^s   Quelapio, M I D ^m   Riekstina, V ^m   Robert, J ^m   Royce, S ^r   Seung, K J ^m   Shah, L ^m   Shim, T S ^m   Shin, S S ^m   Shiraishi, Y ^m   Sifuentes Osornio, J ^s   Strand, M J ^m   Tabarsi, P ^m   Tupasi, T E ^m   Van Altena, R ^m   Van Der Walt, M ^m   Van Der Werf, T S ^m   Viiklepp, P ^m   Westenhouse, J ^m   Yew, W W ^m   Yim, J J ^m   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF SASSARI   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f HOSPITAL F J MUÑIZ   (Argentina)

^g INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^h UNIVERSITY OF INSUBRIA   (Italy)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j STELLENBOSCH UNIVERSITY   (South Africa)

^k HARVARD MEDICAL SCHOOL   (United States)

^l CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^m NONE   (Estonia)

ⁿ NONE   (United States)

^o Vaccinology Department Medical Research Council Unit   (Gambia)

^p NONE   (Mexico)

^q NONE   (Latvia)

^r London   (United Kingdom)

^s Lab of Comparative Neurophysiology   (Mexico)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; TERIZIDONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; ANTIBIOTIC SENSITIVITY; CAUSE OF DEATH; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; META ANALYSIS; MIXED INFECTION; NONHUMAN; PROGNOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84880158505     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00136312     Document Type: Article

References (41)

1. Crofton J. The chemotherapy of tuberculosis. With special reference to patients whose bacilli are resistant to the standard drugs. Br Med Bull 1960; 16: 55-60.
2. Crofton J. Drug treatment of tuberculosis. II. Treatment of patients with tubercle bacilli resistant to standard chemotherapy. Br Med J 1960; 2: 449-451.
3. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva, World Health Organization, 2011.
4. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
5. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
6. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
7. Akcakir Y. Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): A systematic review and meta-analysis. Montreal, McGill University, 2009.
8. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
9. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
10. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430-432.
11. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes -a systematic review and meta-analysis. PLOS Med 2009; 6: e1000146.
12. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, World Health Organization, 2010.
13. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrugresistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
14. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
15. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
16. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
17. Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300: 2153-2160.
18. Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012; 379: 773-775.
19. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
20. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
21. Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
22. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387. (Pubitemid 46348124)
23. Migliori GB, Centis R, D'Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 2012; 54: 1379-1380.
24. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line anti-tuberculosis drugs. Geneva, World Health Organization, 2008.
25. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
26. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, World Health Organization, 2011.
27. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Specific treatment parameters and treatment outcomes of multidrug-resistant tuberculosis: an individual patient data (IPD) meta-analysis of 9153 patients. PLoS Med 2012; 9: e1001300.
28. Higgins JP, Thompson SG. Quantifying heterogeneity in meta-analysis. Stat Med 2002; 21: 1539-1558.
29. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
30. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
31. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
32. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
33. Migliori GB, Zellweger JP, Abubakar I, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807-819.
34. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, emergency update 2008. Geneva, World Health Organization, 2008.
35. Pontali E, Matteelli A, D'Ambrosio L, et al. Re-discovering high-technology from the past: thoracic surgery is back on track for multi-drug resistant tuberculosis. Expert Rev Anti Infect Ther 2012; 10: 1109-1115.
36. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
37. ''Totally drug-resistant TB'': a WHO consultation on the diagnostic definition and treatment options. March 21-22, 2012. www.who.int/tb/challenges/ xdr/xdrconsultation/Date last updated: March 22, 2012. Date last accessed: August 29, 2012.
38. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis. 4th Edn. Geneva, World Health Organization, 2009.
39. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
40. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. The 14-day bactericidal activity of combinations of PA-824, bedaquiline, pyrazinamide and moxifloxacin: the path to novel antituberculosis treatment regimens. Lancet 2012; 380: 986-993.
41. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.